Sinus disease in young children with cystic fibrosis
Funded at University of California Los Angeles · NIH-11333251 · Data updated 2026-11-12
A study will follow children with cystic fibrosis to understand how sinus problems and sense of smell change as they begin highly effective CF medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $552,444 |
| NIH project number | 5R01HL174913-03 |
| Project ID | NIH-11333251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are children diagnosed with cystic fibrosis who are in early childhood and are about to start highly effective CFTR modulator therapy.
✕Less likely to help
Some children with CF who are not candidates for HEMT or who already have long-standing sinus disease may see limited benefit.
What this research studies
This project looks at chronic sinus problems and smell loss in young children with CF, a group not well studied. The team will track how upper airway disease develops and whether early CF medication helps. By combining clinical data and patient experiences, they aim to see if starting treatment earlier improves quality of life and nutrition related to sinus issues. The study uses a prospective design to connect symptoms, infections, and function before and after starting therapy.
Why it matters
Potential benefit: If successful, it could show that early CF therapy improves sinus health and smell, potentially boosting quality of life and overall health for young children with CF.
How similar studies have gone: Earlier work in adults suggests partial improvement in sinus symptoms with CF therapies, but data in young children are lacking and this study addresses that gap.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Beswick, Daniel M — University of California Los Angeles
- Study coordinator: Beswick, Daniel M
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.